iRhythm Holdings Announces Third Quarter 2026 Financial Results

(NASDAQ:IRTC) iRhythm Holdings, Inc. reported financial results for the third quarter ended September 30, 2026. Revenue for the third quarter of 2026 was $221.6 million, representing a 14.9% increase compared to $192.9 million in the third quarter of 2025. Gross profit for the quarter was $164.5 million, up from $137.1 million in the prior year period, with a gross margin of 74.2%, a 310-basis point improvement. The company reported a GAAP net loss of $29.9 million, or $0.90 per diluted share, compared to a GAAP net loss of $5.2 million, or $0.16 per diluted share, in the third quarter of 2025. Adjusted EBITDA for the quarter was $51.2 million, with an adjusted EBITDA margin of 23.1%, representing a $29.6 million and 1,190-basis point improvement, respectively, over the prior year period. Adjusted net income for the third quarter of 2026 was $27.8 million, or $0.82 per diluted share, compared to an adjusted net loss of $2.0 million, or $0.06 per diluted share, in the third quarter of 2025. Operating expenses for the quarter were $197.0 million, compared to $145.6 million in the prior year, while adjusted operating expenses were $138.6 million, down from $141.4 million. Unrestricted cash, cash equivalents, and marketable securities totaled $560.7 million as of September 30, 2026. The company completed the acquisition of VitalConnect on October 5, 2026, broadening its cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering. iRhythm published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT 1), Zio Long-Term Continuous Monitoring (EXCALIBUR 2), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT 3 in over 1.7 million total patients. The company submitted FDA 510(k) applications for pediatric use with its Zio Monitor long-term continuous monitoring business. On November 3, 2026, iRhythm closed a new $300 million senior secured revolving credit facility. For the full year 2026, iRhythm increased its revenue guidance to a range of $890 million to $895 million, including approximately $16 million of expected VitalConnect revenue contribution from the acquisition close through year-end. Adjusted EBITDA margin guidance for 2026 was raised to 15.5% to 16.0%, inclusive of VitalConnect. The company attributes its financial performance to healthy volume-led revenue growth of Zio Monitor, robust margin expansion, and broad-based momentum across cardiology, primary care, innovative channels, and international markets. Quentin Blackford, President and Chief Executive Officer of iRhythm, stated that demand for Zio Monitor exceeded expectations and highlighted the company's focus on advancing innovation, expanding access, and investing in growth initiatives. The company’s total assets as of September 30, 2026, were $1,091,441,000, with total liabilities of $914,335,000 and total stockholders’ equity of $177,106,000. Accounts receivable, net, were $81,126,000, and inventory was $23,222,000 as of September 30, 2026. Accounts payable were $15,395,000, and accrued liabilities were $167,630,000. Long-term senior convertible notes totaled $651,858,000. The company had 33,414 shares issued and 33,185 shares outstanding as of September 30, 2026. The company’s guidance reflects continued volume-led growth and operating leverage while maintaining disciplined investment in innovation and market expansion.

iRhythm Holdings, Inc.: Material Cybersecurity Incidents

(NASDAQ:IRTC) iRhythm Technologies, Inc. filed an Item 1.05: Material Cybersecurity Incidents on 2026-06-15.

iRhythm Holdings Announces First Quarter 2026 Financial Results

iRhythm Holdings, Inc. (NASDAQ: IRTC) reported first quarter 2026 financial results, with revenue of $199.4 million, representing a 25.7% increase compared to the first quarter of 2025. Gross margin improved to 70.9%, a 210-basis point increase, and net loss narrowed to $13.9 million, a $16.8 million improvement year-over-year. Adjusted EBITDA was $14.1 million, with an adjusted EBITDA margin of 7.1%. The company increased its fiscal year 2026 revenue guidance to $875 million to $885 million and adjusted EBITDA margin to 12.0% to 13.0%. Unrestricted cash, cash equivalents, and marketable securities totaled $549.6 million as of March 31, 2026.